NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free DTIL Stock Alerts $11.12 -0.26 (-2.28%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$10.85▼$11.4950-Day Range$9.38▼$14.4552-Week Range$8.25▼$21.90Volume44,861 shsAverage Volume29,911 shsMarket Capitalization$77.06 millionP/E RatioN/ADividend YieldN/APrice Target$46.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Precision BioSciences alerts: Email Address Precision BioSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside316.7% Upside$46.33 Price TargetShort InterestBearish9.50% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.41Based on 3 Articles This WeekInsider TradingSelling Shares$24,218 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.99) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.27 out of 5 starsMedical Sector301st out of 914 stocksBiological Products, Except Diagnostic Industry43rd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 2 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.50% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Precision BioSciences has recently increased by 0.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Precision BioSciences is -0.99. Previous Next 1.9 News and Social Media Coverage News SentimentPrecision BioSciences has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Precision BioSciences this week, compared to 3 articles on an average week.Search Interest6 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,218.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($2.99) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Precision BioSciences Stock (NASDAQ:DTIL)Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More DTIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTIL Stock News HeadlinesJune 5, 2024 | businesswire.comPrecision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver CongressMay 30, 2024 | businesswire.comPrecision BioSciences to Participate in Upcoming June Investor ConferencesMay 29, 2024 | finance.yahoo.comGS Precision and Jeh Aerospace Secure Significant Long-Term Manufacturing PartnershipMay 28, 2024 | tmcnet.comPrecision Neuroscience Announces World Record for Number of Electrodes Placed On Human BrainMay 27, 2024 | msn.comHere's what it's like inside the operating room when someone gets a brain implantMay 17, 2024 | businesswire.comPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comDeep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)May 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)May 14, 2024 | markets.businessinsider.comMaintaining Hold on Precision BioSciences Pending Clinical Data and Strategic ReassessmentsMay 14, 2024 | markets.businessinsider.comPrecision BioSciences Reports Profit From Cont. Ops. In Q1May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong FinancialsMay 13, 2024 | markets.businessinsider.comQuarterly Results Takes Precision BioSciences HigherMay 13, 2024 | businesswire.comPrecision BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | finance.yahoo.comPrecision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private PlacementMay 7, 2024 | finance.yahoo.comPrecision BioSciences to Report First Quarter Results on May 13, 2024May 7, 2024 | markets.businessinsider.comWhy Precision BioSciences Is Rising In Pre-market?May 7, 2024 | finance.yahoo.comPrecision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyMay 7, 2024 | businesswire.comPrecision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyMay 1, 2024 | businesswire.comPrecision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024April 26, 2024 | yahoo.comPrecision Air & Plumbing says if you need a new AC the time is NOWApril 18, 2024 | finanznachrichten.deMillennium Precision LLC Achieves ISO 13485 Certification: A Milestone Towards Excellence and Celebrating 20 Years of Continuous Growth and InnovationApril 17, 2024 | msn.comPrecision BioSciences (DTIL) Price Target Decreased by 22.17% to 36.52April 16, 2024 | msn.comEli Lilly subsidiary, Precision Biosciences end gene therapy collaborationApril 11, 2024 | investing.comPrecision BioSciences Inc (DTIL)April 9, 2024 | yahoo.comPrecision Air & Plumbing offers tips on buying a new AC unit before summer hitsSee More Headlines Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/16/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DTIL CUSIPN/A CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees109Year FoundedN/APrice Target and Rating Average Stock Price Target$46.33 High Stock Price Target$60.00 Low Stock Price Target$19.00 Potential Upside/Downside+316.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($7.4651) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,320,000.00 Net Margins-48.10% Pretax Margin-34.74% Return on Equity-131.69% Return on Assets-22.73% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$48.73 million Price / Sales1.58 Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book2.45Miscellaneous Outstanding Shares6,930,000Free Float6,649,000Market Cap$77.06 million OptionableOptionable Beta1.75 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Amoroso (Age 46)President, CEO & Director Comp: $1.07MMr. John Alexander Kelly R.Ph. (Age 57)CFO & Principal Accounting Officer Comp: $660.91kDr. Alan F. List M.D. (Age 69)Chief Medical Officer Comp: $692.17kDr. Jefferson J. Smith Ph.D. (Age 51)Co-Founder & Chief Research Officer Mei BurrisDirector of Investor Relations & FinanceMr. Dario Scimeca (Age 49)General Counsel & Secretary Comp: $576.43kMr. Bruce StevensVice President of Quality & ComplianceMaurissa MessierSenior Director of Corporate CommunicationsMs. Juli BlancheChief People OfficerMr. Garrett GincleyHead of ManufacturingMore ExecutivesKey CompetitorsFreeline TherapeuticsNASDAQ:FRLNOyster Point PharmaNASDAQ:OYSTSolid BiosciencesNASDAQ:SLDBC4 TherapeuticsNASDAQ:CCCCTenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInsiders & InstitutionsJ. Jefferson SmithSold 50 sharesTotal: $589.50 ($11.79/share)Dario ScimecaSold 93 sharesTotal: $1,096.47 ($11.79/share)Janus Henderson Group PLCBought 573,052 shares on 5/16/2024Ownership: 8.286%Vanguard Group Inc.Sold 4,493,945 shares on 5/10/2024Ownership: 3.771%Acadian Asset Management LLCSold 3,229,642 shares on 5/10/2024Ownership: 1.652%View All Insider TransactionsView All Institutional Transactions DTIL Stock Analysis - Frequently Asked Questions Should I buy or sell Precision BioSciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DTIL shares. View DTIL analyst ratings or view top-rated stocks. What is Precision BioSciences' stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for Precision BioSciences' stock. Their DTIL share price targets range from $19.00 to $60.00. On average, they predict the company's share price to reach $46.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts. How have DTIL shares performed in 2024? Precision BioSciences' stock was trading at $10.95 on January 1st, 2024. Since then, DTIL shares have increased by 1.6% and is now trading at $11.12. View the best growth stocks for 2024 here. When is Precision BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024. View our DTIL earnings forecast. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.10. The firm earned $17.58 million during the quarter, compared to analysts' expectations of $9.35 million. Precision BioSciences had a negative trailing twelve-month return on equity of 131.69% and a negative net margin of 48.10%. What ETF holds Precision BioSciences' stock? Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Matt Kane's approval rating as Precision BioSciences' CEO? 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA). When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (8.29%), Vanguard Group Inc. (3.77%), Acadian Asset Management LLC (1.65%), Moloney Securities Asset Management LLC (0.78%), Vivo Capital LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, J Jefferson Smith, John Alexander Kelly and Michael Amoroso. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DTIL) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredDouble-Threat Biotech Could Deliver Triple-Digit GainsMost investors haven't heard of this under-the-radar biotech... But it could emerge as one of the premier A...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.